other material
confidence high
sentiment positive
materiality 0.60
Eton out-licenses international rights to Increlex to Esteve for €4M upfront
Eton Pharmaceuticals, Inc.
- Esteve pays €4M upfront; license runs up to ten years with option to buy international rights for up to €6M.
- Eton supplies Increlex at a fixed transfer price; no change to expected $80M annual revenue run rate exiting 2025.
- Deal lets Eton focus on three rare-disease product launches planned in the U.S. for 2025.
- Eton eliminates need for significant ex-U.S. commercialization infrastructure investment.